Considering that no signs of toxicity were observed in the clinical trial patients or in tumor-bearing animals treated intracranially, peritumorally, or intraperitoneally with THC, and that no overt toxic effects have been reported in other clinical trials of cannabinoid use in cancer patients for various applications (e.g., inhibition of nausea, vomiting, and pain) and using different routes of administration (e.g., oral, oro-mucosal), our findings support that safe, therapeutically efficacious doses of THC may be reached in cancer patients.
These findings describe a mechanism by which THC can promote the autophagic death of human and mouse cancer cells and provide evidence that cannabinoid administration may be an effective therapeutic strategy for targeting human cancers.” - Harvard Medical School,
The Journal of Clinical Investigation, May 2009, (Manuel Guzmán SP)Plant cannabinoids are stable compounds with low toxicity profiles that are well tolerated by animals and humans during chronic administration.” -“Methods and compositions for treating Cancer”, US9084771, California Pacific Medical Center (Sutter West Bay Hospitals) No signs of toxicity or serious side effects have been observed following chronic administration of cannabidiol to healthy volunteers (Cunha et al., Pharmacology 21:175-185, 1980), even in large acute doses of 700 mg/day -“Cannabinoids as Antioxidants and Neuroprotectants -U.S. Patent 6,630,507"
To summarize, cannabinoids induce tumour cell death and inhibit tumour angiogenesis and invasion in animal models of cancer, and there are indications that they act similarly in patients with glioblastoma. Given that cannabinoids show an acceptable safety profile, clinical trials testing them as single drugs or, ideally, in combination therapies in glioblastoma and other types of cancer are both warranted and urgently needed." -Anticancer mechanisms of cannabinoids" Current Oncology, 2016